Introduction
Paige is a digital pathology company founded in 2017 in New York by Razik Yousfi. It built AI software to analyze digitized cancer tissue slides, assisting pathologists with detection and biomarker assessment in workflows where glass slides were increasingly being scanned into whole-slide imaging systems. On August 22, 2025, Tempus announced the acquisition of Paige for $81.25 million, and Paige now operates as part of Tempus’s broader precision medicine platform rather than as an independent vendor.
For readers mapping consolidation in clinical AI, Paige is one of two major digital pathology acquisitions in a short window — alongside PathAI’s announced merger agreement with Roche in May 2026 — suggesting that pathology AI has moved from venture-backed point solutions to strategic assets for larger diagnostics and data platforms.
Brel profiles Paige as Acquired because the Tempus transaction is completed and disclosed at $81.25 million; readers updating this profile over time should confirm whether Paige continues as a distinct brand within Tempus or is fully absorbed into Tempus product naming.
What the company does
Paige developed FDA-cleared and research-use AI tools for analyzing digitized histopathology images, focusing on cancer diagnostics where pathologist review is the definitive step between biopsy and treatment plan. Its algorithms were designed to integrate with digital pathology scanners and laboratory information systems, providing AI-assisted readouts that pathologists could incorporate into their sign-out workflow. Paige also pursued pharmaceutical partnerships where standardized AI pathology readouts could reduce inter-observer variability in clinical trials.
Digital pathology AI must be validated across scanner vendors, staining protocols, and patient populations — variability that makes standalone algorithm accuracy an insufficient buyer criterion. Laboratories evaluating Paige under Tempus ownership should assess integration depth with their existing digital pathology infrastructure, not only model performance metrics.
Who it serves
Before its acquisition, Paige sold to hospital pathology departments, commercial laboratories adopting digital workflows, and pharmaceutical sponsors. Post-acquisition, Paige’s technology serves Tempus’s existing health-system and life-sciences customer base, extending Tempus’s capabilities from molecular and clinical data into digital slide analysis. Customers evaluating Paige today should look to Tempus for current product availability and support channels.
Company background
Razik Yousfi founded Paige in 2017 in New York City, building on advances in computational pathology and growing hospital investment in slide scanners. The company gained visibility as one of the early digital pathology AI vendors to pursue FDA clearance pathways for clinical decision support in oncology. Tempus’s August 2025 acquisition for $81.25 million, disclosed through Tempus investor relations, marked Paige’s transition from independent company to acquired capability within a larger precision medicine stack led by Eric Lefkofsky in Chicago.
New York’s concentration of academic cancer centers and pathology training programs provided Paige with early clinical collaborators during digital pathology’s transition from research novelty to production laboratory workflow — a shift that accelerated as whole-slide scanner costs fell and pathologist shortages increased interest in AI-assisted review.
Product and AI capabilities
Paige’s AI models applied deep learning to whole-slide images, identifying patterns in hematoxylin-and-eosin stained tissue and in immunohistochemistry markers relevant to cancer diagnosis and treatment selection. The technical challenge in digital pathology AI is not only model accuracy but generalization across scanners, staining protocols, and patient populations — variability that Paige addressed through training on large curated slide libraries and validation studies. Under Tempus ownership, Paige’s pathology AI complements Tempus’s genomic and clinical data layers, enabling multimodal patient profiles that span molecular results and tissue morphology.
Key developments
2017: Paige founded in New York by Razik Yousfi. August 22, 2025: Tempus announced the acquisition of Paige for $81.25 million, per Tempus’s investor relations news release. Paige’s company status is Acquired as of this review.
Why it matters
Paige matters because it was among the first wave of digital pathology AI companies to reach meaningful clinical and regulatory milestones — and because its acquisition by Tempus shows how precision medicine platforms value pathology data as strategic input, not optional add-on. The $81.25 million price point, disclosed officially by Tempus, gives readers a rare verified data point in a sector where private valuations are often opaque. Paige also provides context for PathAI’s later announced Roche merger: two pathology AI leaders absorbed by different acquirer types within months.
For pharmaceutical researchers, Paige under Tempus may accelerate trial pathology standardization if Tempus integrates slide AI into its existing research datasets — but that outcome depends on post-acquisition product decisions Tempus has not fully detailed in the single acquisition announcement Brel cites here.
Sector context
Paige belongs in Brel’s AI in healthcare coverage under digital pathology. Related profiles include acquirer Tempus AI and independent (pending close) PathAI. Readers should treat Paige as acquired and verify current branding and product packaging under Tempus before publication updates.
Digital pathology consolidation in 2025–2026 — Paige to Tempus, PathAI to Roche announced — suggests buyers should evaluate long-term vendor independence as part of procurement, not only algorithm validation metrics.
Sources and references
Tempus investor relations acquisition announcement (August 22, 2025) and Paige company website.
- Tempus — Acquisition of Paige (investors.tempus.com, August 22, 2025)
- Paige — Company website (paige.ai)
Reviewed July 10, 2026.